Veracyte, Inc. (VCYT) P/E Ratio History
Deep ValueTrading at 15.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Veracyte, Inc. (VCYT) trades at a price-to-earnings ratio of 15.8x, with a stock price of $24.16 and trailing twelve-month earnings per share of $1.53.
The current P/E is 76% below its 5-year average of 66.6x. Over the past five years, VCYT's P/E has ranged from a low of 29.9x to a high of 132.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, VCYT trades at a 36% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, VCYT trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VCYT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VCYT Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
VCYT P/E vs Peers
Cancer Diagnostics peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 33.6 | - | -143% | |
| $669M | 12.0Lowest | 1.09 | -3% | |
| $1B | 13.1 | 1.03Best | +105% | |
| $32B | 36.7 | 8.67 | +171%Best | |
| $258B | 36.4 | 17.23 | +7% | |
| $30B | 29.8 | - | +18% | |
| $28B | 25.4 | - | +14% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
VCYT Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Sep 30 2026 | $46.04 | $1.54 | 29.9x | -55% |
| FY2026 Q2 | - | $58.73 | $1.40 | 42.0x | -37% |
| FY2026 Q1 | - | $32.21 | $1.08 | 29.9x | -55% |
| FY2025 Q4 | Dec 31 2025 | $42.10 | $0.82 | 51.6x | -22% |
| FY2025 Q3 | - | $34.33 | $0.38 | 91.4x | +37% |
| FY2025 Q2 | Jun 30 2025 | $27.03 | $0.33 | 83.0x | +25% |
| FY2025 Q1 | Mar 31 2025 | $29.65 | $0.41 | 72.7x | +9% |
| FY2024 Q4 | - | $39.60 | $0.30 | 132.0x | +98% |
Average P/E for displayed period: 66.6x
VCYT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VCYT — Frequently Asked Questions
Quick answers to the most common questions about buying VCYT stock.
What is VCYT's P/E ratio?
Veracyte, Inc. (VCYT) trailing twelve-month P/E ratio is 15.8x, based on TTM diluted EPS of $1.53. The 5-year average P/E is 66.6x and the historical range spans 29.9x to 132.0x.
Is VCYT stock overvalued or undervalued?
VCYT trades at 15.8x P/E, below its 5-year average of 66.6x. At the 0th percentile of its historical range (29.9x–132.0x), the stock is priced at a discount to its own history.
Is VCYT stock expensive?
No, VCYT is not expensive on a historical basis. The current P/E of 15.8x is below the 5-year average of 66.6x and sits at the 0th percentile of its valuation range.
What is VCYT's historical P/E range?
Over the past 5 years, VCYT's P/E ratio has ranged from 29.9x to 132.0x, with a median of 72.7x and an average of 66.6x. The current P/E of 15.8x places the stock at the 0th percentile of this range. Full historical data spans 2024–2026.
How does VCYT's P/E compare to the S&P 500?
VCYT trades at 15.8x P/E versus the S&P 500 median of 21.8x. The 28% discount to the market suggests lower growth expectations or perceived higher risk.
How does VCYT's valuation compare to Healthcare peers?
Veracyte, Inc. P/E of 15.8x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is VCYT's PEG ratio?
VCYT PEG ratio is N/A, based on a P/E of 15.8x and EPS growth of 164.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is VCYT's earnings yield?
VCYT earnings yield is 6.34%, the inverse of its 15.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.